Literature DB >> 30228071

Metabolic characteristics of normal weight central obesity phenotype polycystic ovary syndrome women: a large-scale national epidemiological survey.

Liangshan Mu1, Yue Zhao1, Rong Li1, Yuchen Lai1, Jie Qiao2.   

Abstract

RESEARCH QUESTION: The aim was to investigate the metabolic profiles of women with normal weight but central obesity in polycystic ovary syndrome (PCOS).
DESIGN: In total, 727 women with PCOS from a large-scale epidemiological survey were included. Diagnosis of PCOS was based on Rotterdam criteria. Subjects were categorized into four subgroups: (i) normal weight non-central obesity (NWNCO): body mass index (BMI) ≤18.5 kg/m2 to <25 kg/m2 and waist-to-hip ratio (WHR) <0.85; (ii) normal weight central obesity (NWCO): BMI ≤18.5 kg/m2 to <25 kg/m2 and WHR ≥0.85; (iii) obese non-central obesity (ONCO): BMI ≥25 kg/m2 and WHR <0.85; and (iv) obese central obesity (OCO): BMI ≥25 kg/m2 and WHR ≥0.85. BMI, WHR, blood pressure, glucose and lipid profiles were measured.
RESULTS: NWCO subjects had significantly higher percentages of insulin resistance, high triglycerides and low high-density lipoprotein cholesterol (HDL-C) than NWNCO subjects (all P < 0.05), and similar percentages compared with ONCO subjects. Compared with the NWNCO group, the NWCO group had higher age-adjusted risks of insulin resistance, high triglycerides and low HDL-C (odds ratio [OR] = 3.83, 95% confidence interval [CI] = 2.23-6.58; OR = 1.66, 95% CI = 1.00-2.77, OR = 1.60, 95% CI = 1.11-2.30, respectively).
CONCLUSIONS: PCOS women with normal weight but central obesity had increased risks of insulin resistance and dyslipidaemia compared with normal weight PCOS women without central obesity, suggesting that combining BMI with measurement of central obesity may provide better adiposity-related metabolic risk factor stratification in clinical practice than either method alone.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Body mass index; Insulin resistance; Metabolic syndrome; Obesity; Polycystic ovary syndrome

Mesh:

Substances:

Year:  2018        PMID: 30228071     DOI: 10.1016/j.rbmo.2018.08.007

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  4 in total

Review 1.  The Effect of Metformin on Polycystic Ovary Syndrome in Overweight Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Yuanyuan Guan; Dongjun Wang; Huaien Bu; Tieniu Zhao; Hongwu Wang
Journal:  Int J Endocrinol       Date:  2020-09-16       Impact factor: 3.257

2.  What can be done to improve polycystic ovary syndrome (PCOS) healthcare? Insights from semi-structured interviews with women in Canada.

Authors:  Miya Ismayilova; Sanni Yaya
Journal:  BMC Womens Health       Date:  2022-05-10       Impact factor: 2.742

3.  Transcriptomic Analysis Reveals Endometrial Dynamics in Normoweight and Overweight/Obese Polycystic Ovary Syndrome Women.

Authors:  Su Liu; Ling Hong; Ruochun Lian; Shan Xiao; Yuye Li; Lianghui Diao; Yong Zeng
Journal:  Front Genet       Date:  2022-05-13       Impact factor: 4.772

4.  Lower sexual satisfaction in women with polycystic ovary syndrome and metabolic syndrome.

Authors:  Małgorzata Kałużna; Agnieszka Nomejko; Aleksandra Słowińska; Katarzyna Wachowiak-Ochmańska; Katarzyna Pikosz; Katarzyna Ziemnicka; Marek Ruchała
Journal:  Endocr Connect       Date:  2021-08-30       Impact factor: 3.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.